Evaluation of efficacy and clinical impact of positron emission tomography with 18F fluoro-deoxyglucose in patients with suspicion of recurrent head and neck cancer or distant metastases;Evaluación de la eficacia y el impacto clínico de la tomografía de emisión de positrones con 18F-FDG en pacientes con sospecha de recurrencias locales y metástasis de carcinomas de cabeza y cuello

Revista Espanola de Medicina Nuclear

Volumn 26, Issue 1, 2007, Pages 30-39

  Alvarez Perez R M ^a   Borrego Dorado, I ^a   Ruiz Franco Baux, J V ^a   Vazquez Albertino R J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Clinical impact; Recurrent head and neck cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; WHOLE BODY SCINTISCANNING;

EID: 33847702448     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13097379     Document Type: Article

References (25)

1. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med. 2004;45:56-68.
2. García L, Balsa MA, Mitjavila M. PET en tumores de cabeza y cuello. En: Carreras JL, Lapeña L, Asensio C, editores. PET en Oncología. Madrid: Nova Sidonia Oncología Hematológica; 2002. p. 171-87.
3. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1997;47:5-27.
4. Curtin H, Ishwararn H, Mancuso H, Dalley B, Caudry D, McNeil B. Comparison of CT and MRI imaging in staging of neck metastases. Radiology. 1998;207:123-30.
5. Ojiri H, Mendenhall WM, Mancuso AA. CT findings at the primary site of oropharyngeal squamous cell carcinoma within 6-8 weeks after definitive radiotherapy as predictors of primary site control. Int J Radiat Oncol BiolPhys. 2002;52:748-54.
6. Kao CH, ChangLai SP, Chieng PU, Yen RF, Yen TC. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fluoro-2-deoxyglucose positron emission tomography and comparison with computed tomography. J Clin Oncol. 1998;16:3550-5.
7. Anzai Y, Carroll WR, Quint DJ, Bradford CR, Minoshima S, Wolf GT, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology. 1996;200:135-41.
8. 18F-FDG PET with Conventional Imaging Modalities (MRI, CT, and 67Ga Scintigraphy) in Assessment of Combined Intraarterial Chemotherapy and Radiotherapy for Head and Neck Carcinoma. J Nucl Med. 2003;44:198-206.
9. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology. 2004;231:65-72.
10. BOJA. Resolución 18/2001 de la Dirección General del Sistema Andaluz de Salud.
11. Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope. 2000;110:1493-7.
12. Rege S, Maass A, Chaiken L, Hoh CK, Choi Y, Lufkin R, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer. 1994;73:3047-58.
13. Laubenbacher C, Saumweber D, Wagner-Manslau C, Kau RJ, Herz M, Avril N, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med. 1995;36:1747-57.
14. Wong WL, Chevretton EB, McGurk M, Hussain K, Davis J, Beaney R, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol. 1997;22:209-14.
15. Keyes JW Jr, Watson NE Jr, Williams DW 3rd, Greven KM, McGuirt WF. FDG PET in head and neck cancer. AJR. 1997;169:1663-9.
16. Lowe VJ, Dunphy FR, Varvares M, Kim H, Wittry M, Dunphy CH, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck. 1997;19:666-74.
17. 18F-fluoro- deoxyglucose in detecting residual/recurrent squamous cell carcinoma of head and neck. AJNR 1998;19:1189-96.
18. Sercarz JA, Bailet JW, Abemayor E, Anzai Y, Hoh CK, Lufkin RB, et al. Computer coregistration of positron emission tomography and magnetic resonance images in head and neck cancer. Am J Otolaryngol. 1998;19:130-5.
19. Goerres GW, Schmid DT, Gratz KW, von Schulthess GK, Eyrich GK. Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol. 2003;39:547-51.
20. Schmid DT, Stoeckli SJ, Bandhauer F, Huguenin P, Schmid S, von Schulthess GK, et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope. 2003;113:888-91.
21. Goerres GW, Von Schulthess GK, Hany TF. Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. AJR Am J Roentgenol. 2002;179:1337-43.
22. Porceddu SV, Jarmolowski E, Hicks RJ, Ware R, Weih L, Rischin D, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck. 2005;27:175-81.
23. Kitagawa Y, Nishizawa S, Sano K, Sadato N, Maruta Y, Ogasawara T, et al. Whole-body (18)F-fluorodeoxyglucose positron emission tomography in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:202-7.
24. Kostakoglu L, Hardoff R, Mirtcheva R, Goldsmith SJ. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics. 2004;24:1411-31.
25. Dietl B, Marienhagen J. The therapeutic impact of (I8)F-FDG whole body PET. A radiooncologist's view. Nuklearmedizin. 2005;44:8-14.